Dermatológia pre prax 1/2026
Clinical experience with guselkumab
inhibiting the T helper 17 (Th17) axis and reducing the production of effector cytokines, including interleukin 17A (IL 17A), interleukin 17F (IL 17F) and interleukin 22 (IL 22), which are key drivers of chronic inflammation in psoriasis and related immune mediated disorders. In phase III clinical trials in patients with moderate to severe plaque psoriasis, guselkumab achieved high rates of Psoriasis Area and Severity Index (PASI) 90 and PASI 100 responses and Investigator’s Global Assessment (IGA) scores of 0/1, with durable efficacy maintained for up to 5 years of continuous treatment. Additional analyses confirmed its efficacy in difficult to treat regions and in patients with concomitant psoriatic arthritis, with a consistent and favourable safety profile and no evident increase in serious infections or malignancies.
Keywords: plaque psoriasis, psoriatic arthritis, guselkumab, interleukin 23, IL 23/Th17 axis, biologic therapy